Jump to content

[News] ‘Vacunagate’: Cayetano Heredia University sanctions those responsible for the Sinopharm clinical trial


Recommended Posts

Posted

https://elcomercio.pe/lima/vacunagate-universidad-peruana-cayetano-heredia-sanciona-a-responsables-del-ensayo-clinico-sinopharm-covid-19-vacuna-covid-19-coronavirus-nndc-noticia/

The house of studies has imposed the separation for a period of one year on Germán Málaga Rodríguez, who is involved in the irregular vaccination of 470 people outside of clinical trials, as well as others involved in the case.

The Universidad Peruana Cayetano Heredia (UPCH) announced this Wednesday, July 14, the end of the administrative processes, aimed at evaluating and punishing the faults committed by the main persons in charge of the Sinopharm clinical trial, as a result of the 'Vacunagate' case, which involved vaccination irregular to 470 people outside of studies.

Through a statement, the UPCH explained that the separation for a period of one year has been imposed on Dr. Germán Málaga Rodríguez, and for a period of 6 months on Dr. Hugo García Lescano, as well as a warning to Dr. Javier Palomino busts.

Likewise, the UPCH indicated that it has implemented corrective measures applicable to the 300 research projects it carries out annually, which are aimed at ensuring transparency.

La Universidad Peruana Cayetano Heredia (UPCH) anunció este miércoles el término de los procesos administrativos | Foto: Referencial / El Comercio

ALSO REVIEW | COVID-19 vaccination: more than six million Peruvians were immunized against the disease
"They include the ISO 37001 certification related to anti-bribery practices, internal and external audits, and the strict application of compliance, which is compliance with the standards by each and every member of the university," he said.

In addition, the university has strengthened the role of the Office of Responsible Care in research and has implemented an office exclusively dedicated to regulating and supervising the execution of clinical trials.

  • I love it 1
Guest
This topic is now closed to further replies.
×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.